Free Trial
NASDAQ:XLO

Xilio Therapeutics (XLO) Stock Price, News & Analysis

$0.81
0.00 (0.00%)
(As of 09/17/2024 ET)

About Xilio Therapeutics Stock (NASDAQ:XLO)

Key Stats

Today's Range
$0.74
$0.85
50-Day Range
$0.74
$1.02
52-Week Range
$0.49
$2.89
Volume
442,855 shs
Average Volume
589,814 shs
Market Capitalization
$29.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Xilio Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 40th Percentile

Xilio Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 747th out of 1,014 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Xilio Therapeutics are expected to grow in the coming year, from ($1.26) to ($0.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xilio Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xilio Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Xilio Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Xilio Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.13% of the float of Xilio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Xilio Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Xilio Therapeutics has recently decreased by 72.15%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Xilio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Xilio Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.13% of the float of Xilio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Xilio Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Xilio Therapeutics has recently decreased by 72.15%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Xilio Therapeutics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Xilio Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.20% of the stock of Xilio Therapeutics is held by insiders.

  • Percentage Held by Institutions

    54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Xilio Therapeutics' insider trading history.
Receive XLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

XLO Stock News Headlines

Is Starlink Set For The Largest IPO In History?
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!
See More Headlines

XLO Stock Analysis - Frequently Asked Questions

Xilio Therapeutics' stock was trading at $0.55 at the beginning of the year. Since then, XLO stock has increased by 47.3% and is now trading at $0.81.
View the best growth stocks for 2024 here
.

Xilio Therapeutics, Inc. (NASDAQ:XLO) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.01. The firm had revenue of $2.36 million for the quarter, compared to the consensus estimate of $30 million.

Xilio Therapeutics (XLO) raised $125 million in an IPO on Friday, October 22nd 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share.

Xilio Therapeutics' top institutional shareholders include Renaissance Technologies LLC (0.80%) and XTX Topco Ltd (0.08%). Insiders that own company stock include Gilead Sciences, Inc, Venture Fund Xi LP Atlas, Bain Capital Life Sciences Inv and Rock Springs Capital Managemen.
View institutional ownership trends
.

Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
8/08/2024
Today
9/17/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:XLO
Fax
N/A
Employees
73
Year Founded
N/A

Profitability

Net Income
$-76,400,000.00
Pretax Margin
-2,780.27%

Debt

Sales & Book Value

Annual Sales
$2.36 million
Book Value
$1.34 per share

Miscellaneous

Free Float
34,993,000
Market Cap
$28.07 million
Optionable
Not Optionable
Beta
-0.10
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:XLO) was last updated on 9/18/2024 by MarketBeat.com Staff
From Our Partners